Ranibizumab treatment of retinal vein occlusion

Abstract

The development and approval of anti-VEGF drugs for intravitreal injection has transformed the treatment and prognosis of several ocular conditions, including age-related macular degeneration and retinal vascular occlusion (the subject of this article). Their role in the treatment of ocular conditions is likely to continue to expand owing to the common pathway that VEGF plays in multiple retinal disorders. While important strides have been made, an important treatment challenge is the dosing frequency and the burden that this places on the patient and healthcare providers.

Keywords::

• branch retinal vein occlusion
• central retinal vein occlusion
• Lucentis^®
• ranibizumab
• retinal vein occlusion
• VEGF

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.